News

Reducing distress in caregivers of HSCT recipients


 

Preparation for HSCT

Photo by Chad McNeeley

Research has shown that caring for cancer patients after hematopoietic stem cell transplant (HSCT) can have negative psychological effects on the caregiver, but results of a new study suggest a psychosocial intervention could change that.

The trial showed that counseling sessions focused on stress management could significantly reduce stress, anxiety, depression, and mood disturbance among these caregivers.

“The first 100 days after a stem cell transplant is a critical period for patients, in which caregivers are called upon to deliver around-the-clock care, providing support for patients’ everyday needs and also patients’ emotional health, but who takes care of the caregivers?” asked Mark Laudenslager, PhD, of the University of Colorado Denver.

To address this problem, Dr Laudenslager and his colleagues studied 148 caregivers of patients who underwent allogeneic HSCT. The team described this research in Bone Marrow Transplantation.

The caregivers were randomized to a group that was offered a psychosocial intervention (n=74) and a group that received standard treatment, in which mental health support services were available but not required (n=74).

In the experimental group, caregivers attended 8 sessions on stress management. These one-on-one sessions focused on understanding stress and its physical consequences, changing roles as caregivers, cognitive behavioral stress management, pacing respiration, and identifying social support. The researchers call this intervention PsychoEducation, Paced Respiration and Relaxation (PEPRR).

After a patient underwent HSCT, Dr Laudenslager and his colleagues used several questionnaires to follow the trajectory of caregiver distress over time. The questionnaires were used to measure stress, depression, anxiety, mood disturbance, sleep quality, and other mental health outcomes.

There was no significant difference in stress or other mental health measures between the 2 treatment groups at baseline.

However, at 3 months after transplant, caregivers in the PEPRR group saw some significant improvements over caregivers in the standard treatment group.

The PEPRR group had less stress according to the Perceived Stress Scale (P=0.039), less depression according to the Center for Epidemiologic Studies Depression test (P=0.016), less anxiety according to the State-Trait Anxiety Inventory-State questionnaire (P=0.0009), and less mood disturbance according to the Profile of Mood States-Total Mood Disturbance test (P=0.039).

Overall caregiver distress (composite scores from the questionnaires) was significantly lower in the PEPRR group than the standard treatment group (P=0.019).

However, there was no significant difference in caregiver well-being (composite scores) or scores on the Caregiver Reaction Assessment, Pittsburgh Sleep Quality Index, Short Form 36 Health Survey, or Impact of Events scale.

Still, the other improvements caregivers experienced suggest PEPRR is a promising intervention, Dr Laudenslager said.

He and his colleagues are now recruiting subjects for a follow-up study (NCT02037568) focused on evaluating quality of life in allogeneic HSCT recipients whose caregivers participate in programs similar to the PEPRR intervention.

Recommended Reading

IL-2 variant proves active against ATL, GVHD
MDedge Hematology and Oncology
Combo can fight infection, GVHD
MDedge Hematology and Oncology
Modified T cells may treat GVHD
MDedge Hematology and Oncology
Gene therapy appears effective against WAS
MDedge Hematology and Oncology
Gene therapy superior to partially matched HSCT for SCID-X1
MDedge Hematology and Oncology
Gene appears key to HSC regulation
MDedge Hematology and Oncology
Regulatory monocytes can inhibit GVHD
MDedge Hematology and Oncology
Protein proves essential for hematopoietic recovery
MDedge Hematology and Oncology
Enzyme keeps HSCs functional to prevent anemia
MDedge Hematology and Oncology
EBV-CTLs produce durable responses in EBV-LPD
MDedge Hematology and Oncology